Drawing for MAXMEDIX

USPTO serial 98337940

MAXMEDIX

Reviewed by CopyMark Law Group

Reg. 7763716Status 713
Filing date
Status date
Registration date
Apr 15, 2025
Examiner
DONINGER, CHRISTOPHER G
Law office
TTAB

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with MAXMEDIX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Nakisha Miller

SHANXI WANYIQIAN TECHNOLOGY CO., LTD.ROOM 1303, BUILDING 5, PINGYANG JINGYUANNO. 65, PINGYANG ROAD, XIAODIAN DISTRICTTAIYUAN,SHANXI, 030000

Goods and services

ClassDescriptionStatusFirst use
005Mineral dietary supplements; Lutein dietary supplements; Coenzyme Q10 dietary supplements; Royal jelly dietary supplementsSECTION 18 - CANCELLEDJul 28, 2024

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 26, 2026C18.CANCELLED SECTION 18-TOTAL—
Aug 26, 2026CANTCANCELLATION TERMINATED NO. 999999—
Aug 26, 2026CANGCANCELLATION GRANTED NO. 999999—
Apr 17, 2026PETCCANCELLATION INSTITUTED NO. 999999—
Apr 15, 2025NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Apr 15, 2025R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 22, 2025SUNANOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED—
Mar 22, 2025CNPRALLOWED PRINCIPAL REGISTER - SOU ACCEPTED—
Mar 22, 2025DOCKASSIGNED TO EXAMINER—
Mar 21, 2025SUPCSTATEMENT OF USE PROCESSING COMPLETE—
Mar 21, 2025AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Jan 16, 2025IUAFUSE AMENDMENT FILED—
Jan 16, 2025EISUTEAS STATEMENT OF USE RECEIVEDThe applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action.
Jan 15, 2025EWAFTEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS—
Jan 15, 2025TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jan 15, 2025ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 15, 2025REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Oct 29, 2024NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Sep 3, 2024NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 3, 2024PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 14, 2024NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 31, 2024CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 30, 2024DOCKASSIGNED TO EXAMINER—
Feb 1, 2024NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 4, 2024NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance